IL-17 Inhibitors
IL-17 inhibitors constitute a diverse group of compounds that directly target interleukin-17 or indirectly modulate its signaling pathways. Secukinumab, a representative monoclonal antibody, exemplifies direct inhibition by specifically binding to IL-17A, neutralizing its activity and impeding downstream signaling. Complementing this direct approach, compounds like Ixabepilone disrupt IL-17 indirectly by interfering with the microtubule network, affecting IL-17 trafficking and release. Several compounds act on broader cellular processes to influence IL-17 expression. For instance, Digoxin, a cardiac glycoside, indirectly modulates IL-17 by inhibiting Na+/K+-ATPase, leading to alterations in intracellular ion concentrations. SB203580, a p38 MAPK inhibitor, influences IL-17 expression by suppressing the p38 MAPK pathway, thereby affecting the transcriptional activity of IL-17-related transcription factors. Fluticasone, a glucocorticoid receptor agonist, downregulates IL-17 by interfering with transcriptional activators and co-activators in the IL-17 gene regulatory network.
NF-κB Inhibitor targets the transcription factor NF-κB, critical in IL-17 gene expression, and JAK Inhibitor I disrupts the JAK-STAT signaling pathway associated with IL-17 receptor activation. Dexamethasone, a synthetic glucocorticoid, modulates IL-17 indirectly by inhibiting the transcriptional activity of regulators in the IL-17 expression pathway. Rapamycin, Cyclosporin A, and Tofacitinib influence IL-17 by targeting mTOR, calcineurin, and JAKs, respectively, affecting the balance between regulatory T cells and Th17 cells. Imiquimod, a TLR7 agonist, activates the innate immune response, leading to cytokine release that modulates Th17 and regulatory T cell balance, indirectly influencing IL-17.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $140.00 $680.00 | ||
Cardiac glycoside influencing IL-17 indirectly through the inhibition of Na+/K+-ATPase. The resultant alteration in intracellular ion concentrations affects IL-17 expression and release, modulating the downstream signaling cascades associated with IL-17. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor influencing IL-17 indirectly by suppressing the p38 MAPK pathway. This inhibition downregulates IL-17 expression by modulating the transcriptional activity of key transcription factors involved in IL-17 gene regulation. | ||||||
Fluticasone propionate | 80474-14-2 | sc-218517 | 10 mg | $180.00 | ||
Glucocorticoid receptor agonist with anti-inflammatory properties. It inhibits IL-17 expression by interfering with transcriptional activators and co-activators involved in the IL-17 gene regulatory network, thereby suppressing IL-17-mediated immune responses. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $153.00 $332.00 | 59 | |
Inhibits Janus kinases (JAKs), disrupting the JAK-STAT signaling pathway involved in IL-17 receptor activation. This interference suppresses IL-17-mediated cellular responses by inhibiting the phosphorylation and activation of downstream effectors. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Synthetic glucocorticoid with immunosuppressive effects. It modulates IL-17 indirectly by binding to glucocorticoid receptors and inhibiting the transcriptional activity of key regulators involved in IL-17 expression, thereby dampening IL-17-mediated immune responses. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor disrupting IL-17 signaling indirectly by inhibiting mTOR, a key regulator of T-cell differentiation. This interference alters the balance between regulatory T cells (Tregs) and Th17 cells, leading to suppressed IL-17 production and immune responses associated with IL-17. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Calcineurin inhibitor disrupting IL-17 indirectly by inhibiting T-cell activation. This interference prevents the differentiation of Th17 cells, a major source of IL-17, leading to reduced IL-17 production and downstream signaling. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $66.00 $278.00 | 6 | |
TLR7 agonist influencing IL-17 indirectly by activating the innate immune response. This activation leads to the release of cytokines that modulate the balance between Th17 and regulatory T cells, ultimately affecting IL-17 production and downstream signaling. | ||||||